Highlights

• FY26 sales grew to $15.1m from $13.1m, while the net loss narrowed to $9.9m from $13.9m

• Completed the Full Body CT Critical Design Review and commenced a human imaging study for Head CT

• Secured $1.3m for lung CT scanner research and a $1.3m DHS Checkpoint contract extension

• August 2026 management update and convertible note issue highlight ongoing funding requirements

Micro-X Limited (ASX:MX1) is an Australian medical imaging and security technology company that has developed a unique cold cathode carbon nanotube (CNT) X-ray tube technology. This proprietary technology enables the development of lightweight, portable X-ray and CT scanning devices with significant advantages over conventional thermionic X-ray tubes, particularly in weight, power consumption and precision. Micro-X operates in two primary markets: medical CT imaging (including head, body and lung CT systems) and security screening (including checkpoint and backscatter systems sold to US and international defence and security agencies).

Latest Developments

Micro-X remains more of a technology-development story than a conventional Earnings story. FY26 sales increased to approximately $15.1m from $13.1m, while the net loss narrowed to $9.9m from $13.9m. Operationally, the company has made several important advances: it completed the Full Body CT Critical Design Review, commenced a human imaging study using its Head CT technology, and secured $1.3m for lung-CT scanner research. It also received a $1.3m DHS Checkpoint contract extension. In August, Micro-X announced a management update and convertible-note issue, so funding/cash runway remains an important issue alongside the commercialisation of its CT and security technologies.

Industry Context

The global medical imaging market, particularly portable and point-of-care CT scanning, is experiencing significant growth driven by the healthcare system's push toward decentralised and emergency-focused diagnostic imaging. Traditional CT scanners are large, fixed and expensive, creating a significant market opportunity for compact, portable alternatives in emergency medicine, battlefield casualty care and remote healthcare settings. In the security sector, checkpoint X-ray screening remains a critical infrastructure requirement, with ongoing government Investment in upgraded detection capabilities for airports and border protection.

Key Risks

• Pre-revenue technology development stage means earnings are years away, and cash burn remains a constant concern

• Convertible note issuance indicates funding pressure and potential future dilution for existing shareholders

• Regulatory approval risk for medical CT devices — US FDA clearance pathways are lengthy and uncertain

• Technology risk if competing medical imaging approaches (AI-enhanced conventional CT, MRI advances) reduce the addressable market

• Management change risk following the August 2026 update, which could disrupt commercialisation timelines

Key Catalysts to Watch

• Successful completion of the human imaging study for Head CT technology, enabling regulatory submission preparation

• US FDA clearance or CE marking for any Micro-X CT device — a transformational de-risking event

• Additional DHS or other government security contracts beyond the $1.3m Checkpoint extension

• Strategic Partnership or licensing agreement with a major medical device company for CT technology commercialisation

• Lung CT scanner funding converting into a funded development program with a credible commercialisation pathway

Conclusion

Micro-X (ASX:MX1) sits at the intersection of two large, growing markets — medical imaging and security screening — with genuinely differentiated technology based on its carbon nanotube X-ray platform. FY26 demonstrated continued progress: growing revenue, a narrowing loss and important technical milestones. However, the August convertible note issue is a reminder that funding remains a live issue. MX1 suits speculative investors who can tolerate binary-style technology and Regulatory Risk in exchange for potential significant upside if its CT technologies achieve commercialisation.